[go: up one dir, main page]

WO2009005469A3 - The use of compounds such as pyridoxal derivatives for the treatment of diabetes or diseases associated with the metabolic syndrome - Google Patents

The use of compounds such as pyridoxal derivatives for the treatment of diabetes or diseases associated with the metabolic syndrome Download PDF

Info

Publication number
WO2009005469A3
WO2009005469A3 PCT/SE2008/050831 SE2008050831W WO2009005469A3 WO 2009005469 A3 WO2009005469 A3 WO 2009005469A3 SE 2008050831 W SE2008050831 W SE 2008050831W WO 2009005469 A3 WO2009005469 A3 WO 2009005469A3
Authority
WO
WIPO (PCT)
Prior art keywords
diabetes
compounds
treatment
metabolic syndrome
diseases associated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/SE2008/050831
Other languages
French (fr)
Other versions
WO2009005469A2 (en
Inventor
David Erlinge
Albert S Salehi
Stefan Amisten
Sandra Meidute-Abaravecien
Olov Sterner
Johan Wingstrand
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2009005469A2 publication Critical patent/WO2009005469A2/en
Publication of WO2009005469A3 publication Critical patent/WO2009005469A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/68—One oxygen atom attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/58—Pyridine rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Animal Behavior & Ethology (AREA)
  • Emergency Medicine (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to compounds having the general formula (I), (II) or (III), and which are useful for the treatment or prevention of diabetes or diseases associated with the metabolic syndrome.
PCT/SE2008/050831 2007-07-03 2008-07-03 The use of compounds such as pyridoxal derivatives for the treatment of diabetes or diseases associated with the metabolic syndrome Ceased WO2009005469A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0701617-3 2007-07-03
SE0701617 2007-07-03

Publications (2)

Publication Number Publication Date
WO2009005469A2 WO2009005469A2 (en) 2009-01-08
WO2009005469A3 true WO2009005469A3 (en) 2009-02-26

Family

ID=40226702

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE2008/050831 Ceased WO2009005469A2 (en) 2007-07-03 2008-07-03 The use of compounds such as pyridoxal derivatives for the treatment of diabetes or diseases associated with the metabolic syndrome

Country Status (1)

Country Link
WO (1) WO2009005469A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001078709A2 (en) * 2000-04-12 2001-10-25 Minerva Biotechnologies Corporation Treatment of neurodegenerative disease
WO2003082881A2 (en) * 2002-03-28 2003-10-09 Procyon Biopharma Inc. Pyridoxal-5-phosphate derivatives as hiv integrase inhibitors
US20050053612A1 (en) * 2003-08-20 2005-03-10 Granstein Richard D. Nucleotide regulation of immune responses

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001078709A2 (en) * 2000-04-12 2001-10-25 Minerva Biotechnologies Corporation Treatment of neurodegenerative disease
WO2003082881A2 (en) * 2002-03-28 2003-10-09 Procyon Biopharma Inc. Pyridoxal-5-phosphate derivatives as hiv integrase inhibitors
US20050053612A1 (en) * 2003-08-20 2005-03-10 Granstein Richard D. Nucleotide regulation of immune responses

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BROWN S.G. ET AL.: "Actions of a Series of PPADS Analogs at P2X1, and P2X3 Receptors", DRUG DEVELOPMENT RESEARCH, vol. 53, 2001, pages 281 - 291, XP009011044 *
KIM Y.-C. ET AL.: "Structure-Activity Relationship of Pyridoxal Phosphate Derivatives as Potent and Selective Antagonists of P2X1 Receptors", J. MED. CHEM., vol. 44, no. 3, 2001, pages 340 - 349, XP001018799 *
KIM Y.-C. ET AL.: "Synthesis and Structure-Activity Relationships of Pyridoxal-6-arylazo-5 -phosphate and Phosphonate Derivatives as P2 Receptor Antagonists", DRUG DEVELOPMENT RESEARCH, vol. 45, no. 2, 1998, pages 52 - 66 *
KIM Y.-C. ET AL.: "Synthesis of pyridoxal phosphate derivatives with antagonist activity at the P2Y13 receptor", BIOCHEMICAL PHARMACOLOGY, vol. 70, no. 2, 2005, pages 266 - 274, XP004936151 *
LINGWEI W.: "ADP Acting on P2Y13 Receptors Is a Negative Feedback Pathway for ATP Release From Human Red Blood Cells", CIRCULATION RESEARCH, vol. 96, 2005, pages 189 - 196 *
ZIGANSHIN A.U. ET AL.: "Effect of new pyridoxal phosphate arylazo derivatives on the ecto-ATPase activity in guinea pig tissues", PHARMACEUTICAL CHEMISTRY JOURNAL, vol. 34, no. 5, 2000, pages 226 - 228, XP001000528 *
ZIGANSHIN A.U. ET AL.: "SOME 6-PHENYLAZOPYRIDOXALPHOSPHATE DERIVATIVES INFLUENCE P2-PURINORECEPTOR-MEDIATED EFFECTS", PHARMACEUTICAL CHEMISTRY JOURNAL, vol. 32, no. 8, 1998, pages 399 - 401 *

Also Published As

Publication number Publication date
WO2009005469A2 (en) 2009-01-08

Similar Documents

Publication Publication Date Title
WO2009156462A3 (en) Organic compounds
WO2009043889A3 (en) Oxadiazole derivatives
WO2009051670A3 (en) Oxylipin compounds for the treatment of ophthalmic conditions
WO2008001195A3 (en) Novel processes for the preparation of dpp iv inhibitors
WO2008067219A3 (en) Quinazolinone modulators of tgr5
WO2009152356A3 (en) Compounds and compositions useful for the treatment of malaria
WO2008070129A3 (en) Compositions and methods for the treatment of inflammatory disease
WO2011077043A3 (en) Phenol derivatives and pharmaceutical or cosmetic use thereof
WO2006113919A3 (en) Aryl alkyl acid derivatives for and use thereof
WO2009155001A3 (en) Wnt protein signalling inhibitors
WO2008070268A3 (en) Pharmaceutical compositions
WO2009111700A3 (en) Oxadiazoanthracene compounds for the treatment of diabetes
WO2007003962A3 (en) Gpcr agonists
WO2007003961A3 (en) Gpcr agonists
WO2010063700A8 (en) Novel pyrazole-4 -n-alkoxycarboxamides as microbiocides
WO2007095601A3 (en) Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome
WO2009117421A3 (en) Heterocyclic modulators of gpr119 for treatment of disease
WO2009079008A8 (en) Benzopyrans and analogs as rho kinase inhibitors
WO2008148790A8 (en) Anti -inflammatory substituted cyclobutenedione compounds
WO2011147951A8 (en) Cycloamino derivatives as gpr119 agonists
WO2008073332A3 (en) Creatine compositions for skin treatment
WO2008151828A3 (en) Novel microbiocides
WO2009124962A3 (en) Sulfonamides
WO2008079610A3 (en) Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome
WO2009127718A3 (en) Novel microbiocides

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08779409

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08779409

Country of ref document: EP

Kind code of ref document: A2